

Sarinya Kongpetch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2283050/publications.pdf>

Version: 2024-02-01

21
papers

1,086
citations

687363

13
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

2037
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 1116-1135.	9.4	637
2	Targeting FGFR inhibition in cholangiocarcinoma. <i>Cancer Treatment Reviews</i> , 2021, 95, 102170.	7.7	85
3	Crucial Role of Heme Oxygenase-1 on the Sensitivity of Cholangiocarcinoma Cells to Chemotherapeutic Agents. <i>PLoS ONE</i> , 2012, 7, e34994.	2.5	71
4	Genetics of <i>Opisthorchis viverrini</i> -related cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 258-263.	2.3	45
5	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. <i>JCO Global Oncology</i> , 2020, 6, 628-638.	1.8	35
6	Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 233-244.	2.4	34
7	Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway. <i>Life Sciences</i> , 2018, 207, 172-183.	4.3	29
8	Metformin sensitizes cholangiocarcinoma cell to cisplatin-induced cytotoxicity through oxidative stress mediated mitochondrial pathway. <i>Life Sciences</i> , 2019, 217, 155-163.	4.3	20
9	Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells. <i>Oncology Letters</i> , 2017, 13, 4540-4548.	1.8	19
10	Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells. <i>The American Journal of Chinese Medicine</i> , 2020, 48, 1475-1489.	3.8	18
11	Myricetin ameliorates cytokine-induced migration and invasion of cholangiocarcinoma cells via suppression of STAT3 pathway. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 157.	0.9	18
12	Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2. <i>Anticancer Research</i> , 2015, 35, 6639-53.	1.1	14
13	Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. <i>Life Sciences</i> , 2022, 296, 120427.	4.3	14
14	Cucurbitacin B induces mitochondrial-mediated apoptosis pathway in cholangiocarcinoma cells via suppressing focal adhesion kinase signaling. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 271-278.	3.0	13
15	Phenformin inhibits proliferation, invasion, and angiogenesis of cholangiocarcinoma cells via AMPK-mTOR and HIF-1A pathways. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 1681-1690.	3.0	12
16	All-trans-retinoic acid induces RAR β -dependent apoptosis via ROS induction and enhances cisplatin sensitivity by NRF2 downregulation in cholangiocarcinoma cells. <i>Oncology Letters</i> , 2022, 23, 179.	1.8	6
17	Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma. <i>PeerJ</i> , 2022, 10, e12750.	2.0	5
18	Cucurbitacin B Diminishes Metastatic Behavior of Cholangiocarcinoma Cells by Suppressing Focal Adhesion Kinase. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 219-225.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Derrisalcone suppresses cholangiocarcinoma cells through targeting ROS-mediated mitochondrial cell death, Akt/mTOR, and FAK pathways. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 1929-1940.	3.0	3
20	Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF- κ B Signaling Pathways. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 115-123.	1.2	2
21	Epidermal growth factor receptor as a potential target of momordin Ic to promote apoptosis of cholangiocarcinoma cells. <i>Journal of Pharmacy and Pharmacology</i> , 2022, 74, 996-1005.	2.4	1